Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has issued a Postal Ballot Notice to its members seeking approval for the appointment of Mr. Himanshu Agarwal (DIN: 06672915) as a Whole-Time Director of the Company. This appointment, recommended by the Nomination and Remuneration Committee and approved by the Board on October 28, 2025, is effective from October 29, 2025, for a period of five years, concluding on October 28, 2030. Mr. Agarwal, who currently serves as the Chief Financial Officer, will also continue in that role. The remote e-voting period commences on Wednesday, December 24, 2025, at 9:00 a.m. (IST) and concludes on Thursday, January 22, 2026, at 5:00 p.m. (IST). The results of the postal ballot are expected to be declared on or before January 23, 2026. Mr. Agarwal's remuneration has been detailed, with fixed compensation of ₹3 Crores per annum and variable compensation of ₹60 Lakhs per annum for the financial year 2025-26. From April 1, 2026, his fixed compensation will be revised to ₹3.56 Crores per annum, with variable compensation at ₹71 Lakhs per annum, subject to board-approved targets. The company also disclosed that Mr. Agarwal holds 7,79,092 unvested employee stock options. His profile highlights over 30 years of experience in finance, having previously worked with multinational corporations such as ICI India, Huhtamaki oyj, AkzoNobel India, and Astra Zeneca Pharma Ltd. He is a qualified Chartered Accountant, Cost and Management Accountant, and Company Secretary.